CLINICAL EXPERIENCE WITH A NEW ANTITHYROID DRUG: 2-CARBETH0XYTHI0-1-METHYLGLYOX ALINE*†
- 1 November 1953
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 13 (11) , 1305-1311
- https://doi.org/10.1210/jcem-13-11-1305
Abstract
Clinical experience with a new drug, Neomercazole (C.G.I.) which has a structural formula similar to Tapazole (methimazole) with the H-atom replaced by a carbethoxy group, indicates that it is a potent antithyroid agent. The dose of Neomercazole required for effective antithyroid action is 30-50 mg. daily. Side effects of Neomercazole simulate those of Tapazole with reactions in 3 of 52 patients. Of 2 skin reactions, 1 was very severe; the other slight. In the 3d case, agranulocytosis developed on the 24th day of treatment; recovery followed the withdrawal of the drug and the admn. of antibiotics.Keywords
This publication has 1 reference indexed in Scilit:
- l-METHYL-2-MERCAPTOIMIDAZOLE: A NEW ACTIVE ANTITHYROID AGENT*Journal of Clinical Endocrinology & Metabolism, 1951